IMARC Group’s report titled “Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and Others), Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), Sales Channel (Hospital Pharmacy, Online Providers, Retail Pharmacy), End User (Hospitals, Clinics, Homecare Settings), and Region 2024-2032“. The global non-alcoholic steatohepatitis market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032.
Grab a sample PDF of this report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample
Factors Affecting the Growth of the Non-Alcoholic Steatohepatitis (NASH) Industry:
- Increasing Awareness and Diagnosis:
Heightened awareness among healthcare professionals and people is leading to an increasing vigilance and proactive screening for NASH risk factors and symptoms. Early detection allows for timely intervention and treatment, potentially preventing disease progression, reducing the risk of complications, and improving patient outcomes. Consequently, the emphasis on early diagnosis is driving the demand for diagnostic tests, imaging modalities, and biomarker assays tailored to identify individuals at risk or those already affected by NASH. Moreover, patient advocacy organizations play a crucial role in raising awareness, providing education, and fostering support networks for individuals affected by NASH, thereby amplifying the voice of patients, driving the demand for patient-centered care, and influencing healthcare policy and resource allocation.
- Technological Advancements:
Innovations in technology are leading to the development of advanced diagnostic tools and imaging modalities for NASH detection and monitoring. Non-invasive techniques, such as transient elastography, magnetic resonance elastography (MRE), and ultrasound-based techniques, allow for accurate assessment of liver fibrosis and steatosis without the need for invasive procedures like liver biopsy. These non-invasive diagnostic modalities enhance patient comfort, reduce procedural risks, and facilitate widespread screening and monitoring of NASH, thereby supporting the market growth. Besides this, advancements in omics technologies, including genomics, proteomics, and metabolomics, enable the identification and validation of novel biomarkers associated with NASH pathogenesis, progression, and treatment response.
- Rising Healthcare Expenditure:
As healthcare expenditure is rising, individuals and communities gain greater access to healthcare services, including preventive care, diagnostic tests, and therapeutic interventions for chronic conditions like NASH. Expanded access to healthcare facilities, specialist consultations, and medical treatments enables earlier detection, diagnosis, and management of NASH, driving the demand for related healthcare products and services within the market. In addition, high healthcare expenditure often translates into investments in healthcare infrastructure, medical equipment, and technological advancements, which contribute to improving diagnostic capabilities, treatment modalities, and patient outcomes in NASH care.
Leading Companies Operating in the Global Non-Alcoholic Steatohepatitis Industry:
- Algernon Pharmaceuticals
- Galmed Pharmaceuticals Ltd
- Intercept Pharmaceuticals Inc.
- Zydus Lifesciences Limited
Non-Alcoholic Steatohepatitis Market Report Segmentation:
By Drug Type:
- Vitamin E and Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
Vitamin E and pioglitazone represents the largest segment due to their therapeutic efficacy and established safety profiles.
By Disease Cause:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Obesity accounts for the majority of the market share owing to its strong correlation with the development and progression of the disease.
By Sales Channel:
- Hospital Pharmacy
- Online Providers
- Retail Pharmacy
Retail pharmacy holds the biggest market share as it offers a wide range of medications, including those for managing comorbidities like diabetes and hypertension.
By End User:
- Hospitals
- Clinics
- Homecare Settings
Clinics exhibit a clear dominance in the market, driven by their comprehensive services, including specialized diagnostics, therapeutic interventions, and patient education.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys the leading position in the non-alcoholic steatohepatitis (NASH) market on account of advanced healthcare infrastructure and a robust pharmaceutical industry.
Global Non-Alcoholic Steatohepatitis Market Trends:
The rising integration of artificial intelligence (AI) and machine learning (ML) algorithms into healthcare analytics platforms enables the analysis of complex clinical data, imaging studies, and molecular profiles to identify patterns, predict disease trajectories, and optimize treatment outcomes in NASH patients. AI-powered diagnostic tools, predictive models, and decision support systems aid healthcare providers in risk assessment, treatment selection, and patient management, enhancing clinical decision-making and resource allocation in the NASH market.
Additionally, digital health technologies like telemedicine, remote monitoring devices, and mobile health applications enable remote patient management, real-time data collection, and personalized interventions in NASH care. Digital health solutions facilitate virtual consultations, patient education, medication adherence monitoring, and lifestyle coaching, enhancing patient engagement and treatment adherence while optimizing healthcare resource utilization.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
